
Innoviva (INVA) Stock Forecast & Price Target
Innoviva (INVA) Analyst Ratings
Bulls say
Innoviva is a diversified healthcare company with a strong portfolio of royalty assets, a growing commercial platform focused on critical care and infectious disease, and strategic investments in various healthcare assets. The company's strong financial position, with a solid cash position and future royalty rights, allows for further inorganic growth opportunities, while its current internal marketed products show impressive revenue growth. Additionally, its strategic equity investments, including majority stakes in innovative companies such as Armata and Syndeio, have the potential to drive significant upside for shareholders in the future.
Bears say
Innoviva is heavily reliant on acquisitions for growth, and while management has expressed interest in additional assets, competition in the infectious disease/critical care medicine space is limited, allowing the company to purchase assets at a discount rather than a competitive bid. However, their recent strategic investment in Armata could possibly provide a potential avenue for growth as their antibiotic platform has shown promise in treating antibiotic-resistant bacteria. It remains to be seen how successful this investment will be and the potential impact on Innoviva's overall financials.
This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.
Innoviva (INVA) Analyst Forecast & Price Prediction
Start investing in Innoviva (INVA)
Order type
Buy in
Order amount
Est. shares
0 shares